Kornimate/medical-research-clean huggingface dataset:
low-calorie sweeteners and adipose signaling

Conditions: Nutritional and Metabolic Diseases

Summary: the purpose of this study is to determine whether eight weeks of low-calorie sweetener (lcs) exposure exerts cardiovascular and/or metabolic effects among lcs-naïve overweight and obese adolescents and young adults. we will examine changes in gene expression in subcutaneous fat and will correlate these molecular changes with plasma biochemistry.

the proposed study will investigate lcs-induced changes in metabolically "at-risk" young adults, under conditions that reflect typical beverage consumption. we will first identify molecular pathways potentially affected by lcs (adipose transcriptomics via global rnaseq) and then identify links between lcs-induced gene expression changes and circulating levels of key metabolic biomarkers and clinical outcomes. we will perform subcutaneous adipose biopsies before and after consumption of 12 ounces of diet soda three times daily for eight weeks. within-subjects changes in adipose gene expression will be evaluated using rnaseq. we will then correlate transcriptomic changes with circulating levels of key inflammatory and metabolic biomarkers, to provide mechanistic insight into which pathways drive clinically-relevant lcs-induced metabolic impairments. we will measure glucose, insulin, inflammatory markers and adipose-derived hormones before and after eight weeks of lcs exposure.

Eligibility criteria:
inclusion criteria: 1. female 2. 18-25 years of age 3. overweight and mild to moderate obesity (25 ≤ body mass index (bmi) \<35 kg/m2) 4. consumption of \<1 food/beverage with sucralose and/or acesulfame-potassium per month 5. able and willing to comply with all study procedures for the duration of the study exclusion criteria: 1. overt diabetes 2. renal/gastrointestinal conditions 3. pregnant/lactating 4. recent significant weight change 5. acute illness (w/fever) 6. antibiotics in past 3 months 7. use of illegal drugs/condition limiting ability to give consent.

Keywords: diet soda low-calorie sweeteners obesity
d-0316 in patients with egfr positive non small cell lung cancer

Conditions: Solid Tumor; NSCLC; EGFR T790M

Summary: a phase ii, open label, single-arm study to assess the safety and efficacy of d-0316 in patients with locally advanced/metastatic non small cell lung cancer whose disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapy and whose tumours are epidermal growth factor receptor mutation and t790m mutation positive

this is a phase ii, open label, single arm study assessing the safety and efficacy of d-0316 (firstly, d-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. otherwise, the dose will be maintained at 75mg.) in patients with a confirmed diagnosis of epidermal growth factor receptor mutation positive and t790m mutation positive nsclc,who have progressed following prior therapy with an approved epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki) agent. the primary objective of the study is to assess the efficacy of d-0316 by assessment of objective response rate according to recist 1.1 by an independent central review.

Eligibility criteria:
inclusion criteria: * aged at least 18 years. * histologically or cytologically proven diagnosis of nsclc that is locally advanced or metastatic. * radiological documentation of disease progression while on a previous continuous treatment with an first or second generation of egfr tki e.g. gefitinib or erlotinib. * patients must also have confirmation of tumour t790m mutation status (confirmed positive) after disease progression on the prior egfr tki. * eastern cooperative oncology group performance status (ecog ps) of 0-1. * a minimum life expectancy of 12 weeks. * at least one lesion, not previously irradiated during the study screening period, that can be accurately measured at baseline according to recist 1.1. * agree to use routine adequate and effective contraceptive measures during the entire study period and within 6 weeks after the last dose pre-menopausal fertility possible; female patients need to exclude pregnancy (ie negative pregnancy test) and in non-lactation period. exclusion criteria: * treatment with a first or second generation of egfr-tki within 10 days of study entry; previous treatment with a third generation of egfr-tki. * unresolved toxicities from prior therapy. * unstable spinal cord compression/brain metastases. * severe/uncontrolled systemic diseases, including uncontrolled hypertension, bleeding diatheses or infection. * qtcf≥470 msec（female）or qtcf≥450 msec（male）during the screening period. * severe respiratory diseases such as interstitial lung disease, severe asthma, pulmonary embolism, etc. * previous treatment with 2 or more lines of chemotherapy or immunotherapy.
long-term experience with abatacept sc in routine clinical practice

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to estimate the retention rate of abatacept sc over 24 months in routine clinical practice, in rheumatoid arthritis patients, in each country involved in the study. the purpose of the uk substudy is to explore whether integrating self-assessment into routine care could maintain tight control (of inflammation/disease activity) and at potentially lower cost resulting in improved health outcomes and cost-effectiveness.


Eligibility criteria:
inclusion criteria: * patients ≥18 years old at treatment initiation * patients diagnosed with established moderate to severe active ra as per the 1987 acr criteria/2010 american college of rheumatology (acr)/european league against rheumatism (eular) rheumatoid arthritis classification criteria * patients naïve of abatacept iv and who at their physician's discretion are initiated with abatacept sc. in countries where required (e.g. germany and spain), patients naïve of abatacept iv and who at their physician's discretion have been initiated with abatacept sc at least 1 month prior to enrollment visit up to 6 months if baseline and disease characteristics data are available * for spanish pharmacogenomic sub-study: * caucasian patient and from european ancestry * patient for whom a collection of blood sample before the initiation of abatacept is possible or available (blood sample was taken in routine practice before the study enrolment) * patient who agreed to participate in this substudy and provide a specific signed pharmacogenomic blood rna informed consent * in the uk, the art substudy will be proposed to all patients enrolled in ascore from amendment approval and application date exclusion criteria: - patients who are currently included in any interventional clinical trial in ra
a study of enlicitide decanoate (mk-0616 oral pcsk9 inhibitor) in adults with hypercholesterolemia (mk-0616-013) coralreef lipids

Conditions: Hypercholesterolemia; Familial Hypercholesterolemia

Summary: the goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with hypercholesterolemia. the primary hypothesis is that enlicitide decanoate is superior to placebo on mean percent change from baseline in low-density lipoprotein cholesterol (ldl-c) at week 24.


Eligibility criteria:
inclusion criteria: * has a history of a major atherosclerotic cardiovascular disease (ascvd) event and ldl-c ≥55 mg/dl or, if no history of a major ascvd event, has intermediate to high risk for development of a first major ascvd event and ldl-c ≥70 mg/dl. * is treated with a moderate- or high-intensity statin or is treated with low-intensity statin with documentation of intolerance to a moderate or high-intensity statin or is not receiving statins with documentation of statin intolerance * if on any lipid-lowering therapies (llts), should be on a stable dose with no planned medication change. exclusion criteria: * has a history of homozygous familial hypercholesterolemia (fh) based on genetic or clinical criteria, compound heterozygous fh, or double heterozygous fh * has a history of heart failure or heart failure hospitalization within 3 months before first study visit * is undergoing or previously underwent an ldl-c apheresis program within 3 months before first study visit or plans to initiate an ldl-c apheresis program * was previously treated/is being treated with certain other cholesterol lowering medications, including protein convertase subtilisin/kexin type 9 (pcsk9) inhibitors without adequate washout
patterns of abl mutation in asian with imatinib resistant chronic myeloid leukemia and ph positive acute lymphocytc leuekmia patients (amica)

Conditions: Chronic Myeloid Leukemia or Ph Positive ALL

Summary: the purposes of this study are to investigate the patterns of bcr-abl mutations in cml and ph positive all patients with imatinib resistance during the year of 2001-2009 in asian institutes.

awareness of the significance of bcr-abl mutations is generally low across asia. this is partly due to historical limitations in capabilities for mutation testing. while numerous mutation studies have been done in non-asian populations, there are very few published reports on mutations in asians. cml management in asia therefore continues to be largely intuitive. anecdotal reports, suggest that there may differences in the presence or absence of mutations at the time of initial diagnosis and their occurrence during imatinib treatment. at present, however, we have no comprehensive formal knowledge of the actual nature of mutations in asians. there are moves towards the establishment of cml registries that will capture the pattern of mutations among asian patients. in recent years, several laboratories in the region have been performing mutation analysis. however, no systematic evaluation of or report on these data has been undertaken. this study therefore intends to collect documented mutation data in asian cml and ph positive all patients from identified asian institutes. while this is a retrospective, cross-sectional analysis of mutation information, the study will provide the first comprehensive formal report on mutations in asian cml and ph positive all patients. the collecting information has the potential better to inform the clinical management of cml and ph positive all in asia according to the mutation result and possibly future research in these patients.

Eligibility criteria:
inclusion criteria: * all mutation data from cml and ph positive all patients who developed imatinib resistance during the year 2001-2009 exclusion criteria: * mutation data from cml and ph positive all patients who, in addition to imatinib, received other therapy. follow up mutation report after second generation tki therapy.

Keywords: imatinib resistance mutation
evaluation of three new strategies to fight obesity in families

Conditions: Obesity

Summary: context: endeavours to reduce overweight by calorie-restriction diets are often neither sufficient nor sustained. the growing obesity epidemic demands additional measures to enhance and sustain weight loss. objective: to evaluate three alternative weight-loss measures on top of a calorie-restriction diet. design, setting, and participants: six-month randomized and controlled trial using a three-factorial design. the participants were 110 families with 142 obese parents and their 119 obese children.

intervention: all families kept to a calorie-restriction diet and were assigned at random to one or more of three additional weight-loss strategies: (1) a diet on top of calorie-restriction with preference for carbohydrates having a low glycemic index (dual diet), (2) financial incentive, and (3) continuous telemetric control of weight and physical activity (telemonitoring). the design made it possible to determine the effect of each single measure: financial incentive vs. no financial incentive (54 vs.56 families), calorie-restriction vs. dual diet (53 vs. 57 fami-lies) and telemonitoring vs. no telemonitoring (19 vs. 91 families). the design also allowed an assessment of the effects of combinations of the additional measures, each adapted for possible effects of the other factors. main outcome in the parents the outcome variable at 6 months was the relative weight loss. in children, be-cause of their body growth, the outcome variable was the age-adjusted bmi standard deviation score (bmi-sds). analysis was done by three-factorial anova and by a one-factorial anova with the included dunnett test as a post-hoc comparison, to distinguish between the effects of the different combinations of the additional strategies.

Eligibility criteria:
inclusion criteria: * bmi \> 30 kg/m2 exclusion criteria: * disease of kidney or liver

Keywords: different strategies to fight obesity in families
french cohort of myocardial infarction evaluation

Conditions: Acute Myocardial Infarction

Summary: over the last two decades, considerable progress has been made in the management of acute myocardial infarction (ami), both in the acute phase and in monitoring beyond the hospital phase. nevertheless, the evolution of care practices and their impact on the mid- and long-term prognosis of patients admitted to the intensive care unit for acute myocardial infarction remain relatively little studied exhaustively. the aim of this study is to assess the profile of ami patients, their management and follow-up in order to evaluate the relationship between these factors and outcomes.

the frenchie registry is a french multicenter prospective observational study. all the eligible consecutive patients admitted within 48 hours after symptom onset in a cardiac icu for an acute myocardial infarction. this hospital registry will be linked to the national databases, in order to collect follow-up clinical outcomes and health care consumption.

Eligibility criteria:
inclusion criteria: * myocardial infarction (idm) within 48h of symptom onset, characterized by the typical increased or fall of troponin (or cpkmb) associated with at least one of the following elements : * symptoms compatible with myocardial ischemia * appearance of pathological q waves * st- t changes compatible with myocardial ischemia (st segment elevation or depression, t-wave inversion) * written consent. * covered by french medical insurance ("sécurité sociale") exclusion criteria: * iatrogenic mi defined as mi occurring within 48h of a therapeutic procedure * ami diagnosis invalidated in favor of another diagnosis

Keywords: acute myocardial infarction registry outcomes medico-economic evaluation comorbidities
deep learning using chest x-rays to identify high risk patients for lung cancer screening ct

Conditions: Lung Cancer; Health Screening; Early Cancer Detection; Deep Learning

Summary: the goal of this clinical trial is to evaluate whether an ai tool that alerts providers to patients at high 6-year risk of lung cancer based on their chest x-ray images will improve lung cancer screening ct participation. the main question it aims to answer is: does the ai tool improve lung cancer screening ct participation at 6 months after the baseline outpatient visit the intervention is an alert to the provider to discuss lung cancer screening ct eligibility, for patients considered at high risk of lung cancer based on cxr-lc ai tool. if there is a comparison group: researchers will compare intervention and non-intervention arms to determine if lung cancer screen ct participation increases.


Eligibility criteria:
major inclusion criteria: * scheduled outpatient appointment with participating provider. * 50- to 77-year-old who currently or formerly smoked, to include persons potentially eligible for lung screening based on medicare guidelines. * recent (within 2 years) pa chest radiograph. exclusion criteria: • history or signs/symptoms of lung cancer. recent (within 2 years) chest ct. clinical indication for chest ct beyond lung cancer screening.

Keywords: deep learning ai chest x-ray
surgery for large angle exotropia two muscles versus three muscles

Conditions: Exotropia

Summary: comparison between the results of two muscles surgery and three muscles surgery for the treatment of large angle exotropia

exotropia is classified as primary which includes constant and intermittent exotropias. secondary xt include sensory and consecutive xt. management for ixt consists of non-surgical and surgical treatment. there is some controversy regarding the optimal surgical method varying between bilateral lateral rectus recession (blr), unilateral lateral rectus recession-medial rectus resection (rr) and bilateral medial rectus resection (bmr).

Eligibility criteria:
inclusion criteria: * patients above age of 5 years with concomitant exotropia of (40-55) pd of any type. exclusion criteria: 1. angle of deviation less than 40 pd or more than 55 pd. 2. history of previous surgery. 3. inconcomitant exotropia. 4. incomitance in any gaze. 5. associated vertical deviation(oblique dysfunction,a or v pattern). 6. patients with neurological deficit.
reduction of intraoperative eeg burst suppression

Conditions: Burst Suppression; EEG With Abnormally Slow Frequencies; Postoperative Delirium

Summary: burst suppression (bs) is a not physiological pattern in the electroencephalogram (eeg). bs during general anesthesia is mainly seen as a sign for too deep hypnosis and may increase the risk of postoperative delirium (pod), a disturbance of consciousness arising within 24 hours after surgery. this monocentric, simple masked randomized study aims primarily to investigate, whether particular anesthesiological interventions reduce the occurrence of intraoperative burst suppression. the investigator initiated trial includes 66 patients (male and female) aged ≥ 60 years in two groups (intervention and control group). secondary aims will be the correlation of burst suppression and mean arterial pressure, concentration of anesthetics and postoperative delirium.

intraoperative burst suppression represents a non physiological eeg pattern. according to the literature and scientific knowledge, intraoperative burst suppression patterns might be caused either by hypotension resulting in a reduced cerebral circulation or by an oversedation of anesthetics correlating with a very deep level of hypnosis. some publications exist that discuss the occurrence of intraoperative burst suppression especially in elderly people (aged ≥ 60 years) as a predictor of postoperative delirium and postoperative cognitive dysfunction. none of the studies however was able to prove a causal relationship between burst suppression and postoperative delirium. contrary it might simply be an epiphenomenon. conducting this interventional trail primarily aims to prove whether specific anesthesiological interventions, such as the treatment of intraoperative hypotension in first line and/or the reduction of the concentration of anesthetics in second line, reduce intraoperative burst suppression. hence it might be possible to investigate a possible casualty between burst suppression and postoperative delirium in a second trial.

Eligibility criteria:
inclusion criteria: * age ≥ 60 years * surgical interventions in general anesthesia (volatile or total intravenous anesthesia) * expected surgery duration ≥ 1h * american society of anesthesiologists (asa) 1-4 * written informed consent prior to study participation exclusion criteria: * neurological or psychiatric disorders * hearing difficulty * deafness * neurosurgical (intra)cranial surgery * pregnancy * expected continuous mandatory ventilation after surgery

Keywords: intraoperative eeg based monitoring level of hypnosis burst suppression postoperative delirium eeg-signal characteristics entropy
patient satisfaction and oral healthy related quality of life of polyetherketoneketone and metal framework.

Conditions: Patient Satisfaction

Summary: the patients' satisfaction and oral health related quality of life (ohrql) of different framework material remains uncertain. thus, the aim of this clinical cross over study was to compare patient satisfaction and ohrql of polyetherketoneketone and metal framework for all-on-four implant supported fixed prosthesis

10 completely edentulous patients around age of 50-60 years will be selected for this study from the outpatient clinic, faculty of dentistry, mansoura university. all selected participants will receive a new complete dentures (cd) fabricated with bilateral balanced occlusion utilizing semi-anatomical acrylic teeth. the patients were instructed to wear the dentures for 3 months to develop adequate neuromuscular control, and then, clinical performance and patient satisfaction will be evaluated. each participant will receive 4 implants according to the "all-on-4 concept," and the implants will be immediately loaded with mandibular denture. three months after osseointegration, patients received a definitive fixed detachable prosthesis either from pekk or metal with composite teeth in a crossover designs. two sets of patients will be made (10 patients/set) using random-generated numbers created by a computer program (excel sheet). the first 10 participants will recieve metal framework first. after 3 months, patient satisfaction and ohrqol will be measured and metal framework will be replaced by pekk framework. after another 3 months, measurements will be repeated. the second 10 patients received pekk first, and after 3 months, measurements will be made. then, pekk framework was replaced by metal framework and measurements were repeated after another 3 months.

Eligibility criteria:
inclusion criteria: * sufficient available restorative space (from the proposed occlusal plane to soft tissue • covering residual ridge) of at least 20 mm to accommodate all types of tested prosthesis. * they had completely edentulous maxilla and mandible at least six months after the last extraction. * sufficient residual alveolar ridge quantity and quality (d2-d3) * maxillary and mandibular residual alveolar ridges covered by healthy non-inflamed mucosa with even compressibility. * normal maxillo-mandibular relationship. exclusion criteria: all diseases or syndromes are contraindicated with implant surgery such as: * general contraindications for surgical procedures such as patients with head and neck radio therapy, patients with bleeding disorders, hepatic patients. * patients with metabolic disorders that affect osseo integration such as diabetes mellitus, and osteoporosis. * long term immunosuppressive and corticosteroid drug therapy. * abnormal detrimental habits, e.g. bruxism and clenching. * heavy smokers and alcoholic patients. * all patients will be informed about the steps involved in this research and they will sign a written consent form of the ethical committee of faculty of dentistry mansoura university for approval to take part in this research and come to the follow up visits.